Across TCGA pan-cancer cohorts, CXCL17 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CXCL17 data layer compared with 22 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher CXCL17 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CXCL17 expression acts as an unfavorable survival marker.

COAD and LIHC are the cancer types where CXCL17 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	All	0.487	0.871	<.001	35	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: CXCL17 tumor-vs-normal RNA expression · all CXCL17 data types